(Q36607401)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17009940%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

review article

1 reference

title

Treatment options for multidrug-resistant bacteria (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17009940%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

main subject

multiple drug resistance

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17009940%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

Helen Giamarellou

series ordinal

1

1 reference

15 August 2017

publication date

1 August 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17009940%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anti-infective Therapy

20 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17009940%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17009940%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17009940%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

601-618

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17009940%20AND%20SRC:MED&resulttype=core&format=json

Epidemiology of drug resistance: implications for a post-antimicrobial era

20 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Antimicrobial resistance trends and outbreak frequency in United States hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Multi-resistant Gram-negative bacilli: from epidemics to endemics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Lack of development of new antimicrobial drugs: a potential serious threat to public health

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Why is big Pharma getting out of antibacterial drug discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Development of drugs for antimicrobial-resistant pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

The antibiotic pipeline--challenges, costs, and values

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Antimicrobial drug development--the past, the present, and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Community-acquired methicillin-resistant Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Vancomycin-resistant Staphylococcus aureus: no apocalypse now

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Vancomycin-resistant enterococci: consequences for therapy and infection control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Multidrug resistance in Gram-negative bacteria that produce extended-spectrum beta-lactamases (ESBLs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Surveillance of antibiotic resistance in European ICUs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Detection of extended-spectrum beta-lactamases in members of the family enterobacteriaceae: comparison of the MAST DD test, the double disc and the Etest ESBL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Emerging metallo-beta-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Metallo-beta-lactamases: the quiet before the storm?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

OXA (beta)-lactamases in Acinetobacter: the story so far.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Polymyxin and Related Peptide Antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Interaction of divalent cations and polymyxin B with lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Evidence for two distinct mechanisms of resistance to polymyxin B in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Temperature-regulated efflux pump/potassium antiporter system mediates resistance to cationic antimicrobial peptides in Yersinia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Evaluation of the anti-endotoxic effects of polymyxin-E (colistin) in dogs with naturally occurred endotoxic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

A reassessment of the in-vitro activity of colistin sulphomethate sodium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

BSAC standardized disc susceptibility testing method.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Residue determination of two co-administered antibacterial agents--cephalexin and colistin--in calf tissues using high-performance liquid chromatography and microbiological methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Binding of polymyxin antibiotics to tissues: the major determinant of distribution and persistence in the body.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Nephrotoxicity of intravenous colistin: a prospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Toxicity after prolonged (more than four weeks) administration of intravenous colistin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Bronchoconstriction following nebulised colistin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Pharmacokinetics of ampicillin-sulbactam in healthy elderly and young volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Tigecycline: a new glycylcycline for treatment of serious infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

In vitro activities of tigecycline against the Bacteroides fragilis group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

The pharmacokinetic and pharmacodynamic profile of tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Thrombocytopenia associated with linezolid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Peripheral neuropathy associated with prolonged use of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Risk factors for arthralgias or myalgias associated with quinupristin-dalfopristin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Severe myopathy and possible hepatotoxicity related to daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Glycopeptides: Update on an old successful antibiotic class

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Oritavancin: a new avenue for resistant Gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Antistaphylococcal activity of dalbavancin, an experimental glycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

The antimicrobial armamentarium: evaluating current and future treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Cationic antimicrobial peptides: towards clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.601

21 January 2018

Identifiers

DOI

10.1586/14787210.4.4.601

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17009940%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference